Salinosporamides and methods for use thereof
View Patent ↗The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC 50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.
1. A method of treating a mammalian cell proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure:
thereby treating a mammalian cell proliferative disorder, wherein the proliferative disorder is selected from the group consisting of mammary neoplasm, non-small-cell lung neoplasm, leukemia neoplasm, melanoma neoplasm, pancreatic adenocarcinoma neoplasm, central nervous system neoplasm, ovarian neoplasm, prostate neoplasm, myeloma neoplasm, non-Hodgkin's neoplasm, and Hodgkin's neoplasm.
2. The method of claim 1 , wherein the mammalian cell is human.
3. The method of claim 1 , wherein the proliferative disorder is a mammary neoplasm.
4. The method of claim 1 , wherein the proliferative disorder is a non-small-cell lung neoplasm.
5. The method of claim 1 , wherein the proliferative disorder is a leukemia neoplasm.
6. The method of claim 1 , wherein the proliferative disorder is a melanoma neoplasm.
7. The method of claim 1 , wherein the proliferative disorder is a pancreatic adenocarcinoma neoplasm.
8. The method of claim 1 , wherein the proliferative disorder is a central nervous system neoplasm.
9. The method of claim 1 , wherein the proliferative disorder is an ovarian neoplasm.
10. The method of claim 1 , wherein the proliferative disorder is a prostate neoplasm.
11. The method of claim 1 , wherein the proliferative disorder is a myeloma neoplasm.
12. The method of claim 1 , wherein the proliferative disorder is a non-Hodgkin's neoplasm.
13. The method of claim 1 , wherein the proliferative disorder is a Hodgkin's neoplasm.
14. The method of claim 1 , wherein the compound has the structure:
15. The method of claim 14 , wherein the proliferative disorder is a mammary neoplasm.
16. The method of claim 14 , wherein the proliferative disorder is a non-small-cell lung neoplasm.
17. The method of claim 14 , wherein the proliferative disorder is a leukemia neoplasm.
18. The method of claim 14 , wherein the proliferative disorder is a melanoma neoplasm.
19. The method of claim 14 , wherein the proliferative disorder is a pancreatic adenocarcinoma neoplasm.
20. The method of claim 14 , wherein the proliferative disorder is a central nervous system neoplasm.
21. The method of claim 14 , wherein the proliferative disorder is an ovarian neoplasm.
22. The method of claim 14 , wherein the proliferative disorder is a prostate neoplasm.
23. The method of claim 14 , wherein the proliferative disorder is a myeloma neoplasm.
24. The method of claim 14 , wherein the proliferative disorder is a non-Hodgkin's neoplasm.
25. The method of claim 14 , wherein the proliferative disorder is a Hodgkin's neoplasm.
26. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure:
wherein the cancer is selected from the group consisting of mammary, non-small-cell lung, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system neoplasm, ovarian, prostate, myeloma, non-Hodgkin's cancer and Hodgkin's cancer.
27. The method of claim 26 , wherein the compound has the structure: